#-supreme-cart-case-studies-11-2805{picked-cards-data:[];manual-cards-data:[{"image":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/09\/cropped-Logo-1.png","image_alt":"Billings Clinic Cancer Center","badge":"Case Study","heading":"Practice Profile:Billings Clinic Cancer Center","text":"ACCC's profile of how a rural health system stood up a CAR-T program,covering implementation,staff education and communication with referring providers. \n","url":"\/wp-content\/uploads\/2026\/09\/practiceprofile-billing-clinic.pdf","new_tab":"true"},{"image":"https:\/\/communitycart.org\/wp-content\/uploads\/2026\/09\/cropped-Logo-1.png","image_alt":"Targeted Oncology Article","badge":"Case Study","heading":"Targeted Oncology Article","text":"\"Expanding CAR T-Cell Therapy in Community Oncology\" Virginia Cancer Specialists built a community CAR-T program,covering leadership,care pathways,team,hospital partners,payers,and early cases","url":"https:\/\/www.targetedonc.com\/view\/expanding-car-t-cell-therapy-in-community-oncology-a-critical-next-step-for-access","new_tab":"true"}]}#-supreme-cart-checklist-6-2805{items-data:[{"text":"Clinical space assessed and appropriate"},{"text":"Receipt,Chain of Custody and drug handling protocols in place"},{"text":"Apheresis capability confirmed (in-house or referral)"},{"text":"Emergency Care access secured for CRS\/ICANS management"},{"text":"Monitoring plan established for the post-infusion period"},{"text":"Staffing and training plan complete"},{"text":"Written agreements signed with hospital,collection and lab partners"},{"text":"After-hours and 24\/7 escalation route documented and tested"},{"text":"Inpatient or outpatient administration decision documented"}]}#-supreme-cart-playbook-navigation-8-2805{topics-data:[{"title":"Contracting & Partnerships","description":"Terms with manufacturers,payers,and partners.\n","url":"\/playbook\/contracting-and-partnerships\/","cta_text":"Explore ","accent":"blue"},{"title":"Patient Selection & Support","description":"Identify,refer,and support eligible patients.","url":"\/playbook\/patient-selection-and-support\/","cta_text":"Explore ","accent":"pink"},{"title":"Guidance for CAR T-related adverse reactions ","description":"Recognize and manage toxicities on site.","url":"\/playbook\/guidance-for-car-t-related-adverse-reactions\/","cta_text":"Explore ","accent":"pink"}]}#-supreme-cart-staffing-training-4-2805{cards-data:[{"title":"Clinical Lead","description":"A medical director,physician or advanced practice nurse holding clinical accountability. Cellular therapy training or experience in BMT may help with speed of adoption."},{"title":"Program Coordination","description":"Guides each patient from referral through follow-up and keeps physicians,apheresis,pharmacy,the manufacturer,reimbursement and your partner hospital on one timeline."},{"title":"Receipt & Product Handling","description":"Owns receipt,chain of identity and custody,storage or thaw scheduling,and immediate tocilizumab availability on infusion day."},{"title":"Quality Management","description":"A designated role covering SOPs,training and competency records,outcome reporting and the written agreements you hold with collection,laboratory and hospital partners."}]}#-supreme-faq-accordion-3-2805{faqs-data:[{"question":"Clinical Space","answer":"<p>Identifying space for infusion and for post-infusion monitoring is a distinct planning step,not an assumption. A hospital setting isn&rsquo;t needed,but having a close working relationship with a collaborating hospital for adverse event management is wise. Whatever space you use,think through how you may manage any potential side effects.</p>"},{"question":"Receipt & Drug Handling","answer":"The product arrives in a vapor-phase nitrogen dry shipper. The first checks are to ensure packaging integrity,transit temperature,bag integrity,labeling,number of bags and expiry. Chain of identity verified again against the identifiers which were recorded at collection. If storing,on-site storage needs temperature monitoring with 24-hour alarms. Some centers choose to deliver just-in time,because thawed cells stay stable for only about 30 to 90 minutes. Receiver and the infusion team work to one schedule to ensure correct delivery."},{"question":"Apheresis Capability","answer":"Leukapheresis is commonly performed in an outpatient community setting. The apheresis order is best placed in the same system as the CAR-T prescription so washout periods for G-CSF,cytotoxics and steroids can be verified. Chain of custody is critical including double-checking the bag against patient identifiers and the Donation Identification Number. If building a unit is not realistic,apheresis is among the services most readily contracted to a qualified provider."},{"question":" Emergency Care ICU Access","answer":"Side effects from CAR-T therapies can be serious,but are manageable,and they need fast escalation. A defined pathway matters more than owning an emergency department or ICU. Work through ambulance,emergency department,ICU,neurology and cardiology together,and agree admission criteria before the first patient rather than during. Ensure you have the necessary medications to manage side effects on hand per patient."},{"question":"Monitoring Capabilities","answer":"Patients must stay near the treating facility up to two weeks. Daily assessment for the first seven days and weekly review for at least a month,through in-person visits or remote monitoring. Work with your product manufacturer to best understand monitoring timing. A critical importance for smaller practices is to plan after-hours,weekend and holiday monitoring. For events outside of business hours,a dedicated line that bypasses emergency services is one option to consider."}]}